Equities

Jenscare Scientific Co Ltd

Jenscare Scientific Co Ltd

Actions
Health CareMedical Equipment and Services
  • Price (HKD)3.97
  • Today's Change0.00 / 0.00%
  • Shares traded2.79m
  • 1 Year change-87.59%
  • Beta--
Data delayed at least 15 minutes, as of May 31 2024 09:08 BST.
More ▼
Improved Notifications for Markets Data Alerts
Improved Notifications for Markets Data Alerts
Want push notifications sent directly to your devices for equity price changes and breaking news stories? Let us know here.
 
Existing alertsView our existing alerts
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Jenscare Scientific Co Ltd is a China-based company mainly engaged in the manufacturing and research and development of medical devices. The Company develops interventional products for the treatment of structural heart disease. The Company's core products include LuX-Valve and Ken-Valve. LuX-Valve is a transcatheter tricuspid valve replacement system designed for patients with severe tricuspid regurgitation and high surgical risk. Ken-Valve is designed for the treatment of severe aortic regurgitation or combined with aortic stenosis. The Company also develops product candidates for the treatment of mitral valve diseases and medical devices for the treatment of heart failure. The Company mainly conducts its businesses in the domestic market.

  • Revenue in HKD (TTM)0.00
  • Net income in HKD-401.83m
  • Incorporated2011
  • Employees376.00
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Austar Lifesciences Ltd1.91bn-35.25m420.32m1.61k--0.503034.780.2205-0.0688-0.23933.721.630.77573.561.851,184,180.00-1.534.39-3.449.9819.0523.09-1.974.561.07--0.39020.00-18.2316.65-131.28--67.92--
China Health Group Ltd74.43m-29.50m440.68m133.00--5.85--5.92-0.0651-0.06510.16410.15720.25363.823.03543,313.90-9.74-10.57-17.56-21.4233.6233.05-38.40-32.700.9156-4.910.0765---28.6025.81-244.50--50.63--
Shanghai Bio-heart Biologicl Tech Co Ltd0.00-190.13m485.43m32.00--0.600-----0.7811-0.78110.003.320.00----0.00-20.99---22.30----------20.16--0.0023------13.88------
Ziyuanyuan Holdings Group Ltd538.27m15.74m554.70m184.0032.781.5318.221.030.03940.03941.350.84440.81844.543.022,925,383.002.282.613.673.7124.69--2.786.131.752.340.313--53.4152.48-7.90-2.9897.56--
Shanghai HeartCare Medcl Tech Corp Ltd251.16m-101.62m698.24m368.00--0.6005--2.78-2.67-2.676.6029.940.18490.49314.54682,486.40-7.48---7.88--70.48---40.46--14.37--0.0327--26.94--53.08------
Guanze Medical Infrm Indstry (Hldng) Ltd168.71m29.80m950.00m56.0031.883.2625.905.630.03140.03140.17760.30650.48765.371.203,012,641.008.72--10.54--54.72--17.89--6.252,148.220.0748---11.88--53.63------
MicroTech Medical Hangzhou Co Ltd273.73m-135.14m1.49bn760.00--0.7548--5.45-0.3175-0.31750.6435.230.11372.354.13360,170.20-5.62---5.85--49.13---49.37--21.22--0.00008--45.92---256.75------
PW Medtech Group Ltd729.74m165.59m1.53bn1.24k9.270.3514.682.100.10580.10580.46612.790.13312.199.21586,607.804.047.234.918.0956.4258.1330.3785.3812.70--0.00024.1125.7516.7844.465.94-7.92--
ClouDr Group Ltd3.99bn-349.22m1.57bn1.52k--0.7253--0.3929-0.6455-0.64557.383.681.285.484.742,621,110.00-11.33---17.13--24.64---8.87--1.58-29.150.1314--23.51--80.87------
Jenscare Scientific Co Ltd0.00-401.83m1.66bn376.00--1.24-----0.9632-0.96320.003.190.00----0.00-27.49---28.61----------19.20--0.0347------15.38------
IVD Medical Holding Ltd3.34bn257.45m1.67bn803.006.460.46085.610.49910.19040.19042.472.670.67882.785.624,157,445.005.215.186.866.6721.7520.757.687.531.567.530.0923--12.3549.4913.4118.1519.77--
Sisram Medical Ltd2.81bn246.24m1.76bn1.08k7.150.4984.780.6270.52560.52566.007.550.61471.804.392,600,642.005.635.946.706.8861.1057.669.1610.582.0013.960.086928.791.3618.48-21.597.6146.589.64
Venus MedTech HangZhou Inc531.16m-760.73m2.48bn865.00--0.785--4.67-1.74-1.741.217.160.10140.94021.65614,052.60-15.04-13.20-17.41-14.9779.2179.51-148.37-152.831.86-8.780.2206--20.8933.6233.46--58.20--
Data as of May 31 2024. Currency figures normalised to Jenscare Scientific Co Ltd's reporting currency: Hong Kong Dollar HKD

Institutional shareholders

0.94%Per cent of shares held by top holders
HolderShares% Held
Huashang Fund Management Co., Ltd.as of 31 Dec 20231.20m0.39%
Guotai Asset Management Co., Ltd.as of 31 Dec 2023472.00k0.15%
GF Fund Management Co., Ltd.as of 31 Dec 2023441.80k0.14%
Truvalue Asset Management Co. Ltd.as of 31 Dec 2023288.40k0.09%
Great Wall Fund Management Co., Ltd.as of 31 Dec 2023272.60k0.09%
China Merchants Fund Management Co., Ltd.as of 31 Dec 2023156.40k0.05%
Minsheng Royal Fund Management Co., Ltd.as of 31 Dec 202331.00k0.01%
China International Capital Corp. Ltd. (Invt Management)as of 31 Dec 202324.80k0.01%
Cinda Fund Management Co. Ltd.as of 31 Dec 20238.00k0.00%
Fullgoal Fund Management Co., Ltd.as of 31 Dec 20233.20k0.00%
More ▼
Data from 31 Dec 2023 - 31 Dec 2023Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.